



## **CBD MED RESEARCH CORP**

#810 – 675 W. Hastings Street, Vancouver, B.C., Canada V6B 1N2  
Tel: 604-802-7551 • [www.cbdmedresearch.com](http://www.cbdmedresearch.com)

**CBD MED RESEARCH CORP. ("CBM" or the "Company")**

**TSX.V NEX Symbol: CBM.H**

### **CBD Med Research Corp. Announces LOI to acquire Exclusive Drug Delivery System Distribution Rights in Canada.**

June 25, 2015: CBD Med Research Corp. (“The Company”) is pleased to announce it has negotiated a Letter Of Intent with Medipacs Inc. to acquire the exclusive distribution rights of the “**Mini-Infusion™ Pump**”, in Canada.

Medipacs Inc., a drug infusion technology company, based in San Diego, California, ([www.medipacs.com](http://www.medipacs.com)) has spent \$10 million dollars on development and secured 22 issued and pending patents on novel polymer technology. The Medipacs wearable **Mini-Infusion™ Pump** represents a new class for injectable drug delivery systems. In essence, a wearable infusion pump is a system that can be worn on the body of a patient while it delivers the medication into the body. Mark McWilliams, president of Medipacs stated “Medical Technology experts that have reviewed the Medipacs technology platform believe it is the end game in infusion pump design because with one moving part, it is the simplest of designs, yet the most versatile wearable infusion platform yet developed.”

The Medipacs **Mini-Infusion™ Pump** provides a completely new approach to small volume parenteral drug administration. A revolutionary new programmable micro-pump technology that combines the accuracy of electronically controlled pump technology with the low cost and convenience of a lightweight, disposable wearable infusion device. The product offers compelling clinical benefits that improve therapy across all sites of care.

The Medipacs technology is able to displace drugs from an internal drug container accurately, with only one moving part...the expanding polymer. The patented process allows for a small, lightweight, wearable, **Mini-Infusion™ Pump** to deliver personalized medicine solutions to humans and animals for days.

### **USA INFUSION PUMP MARKET**

The new market for infusion pumps reported “by Millennium Research Group in November 2012” stated that the USA Infusion pump market to grow strongly to \$3.6 billion by 2017.

(Transparency market research, reported May 28, 2015) “The Global Infusion Pump market is encountering momentous growth due to the rising patient pool having chronic pain, diabetes and cancer due to increasing geriatric population.”

Infusion Pumps are used to infuse/inject necessary fluids, including medications and or nutrients, to a patients circulatory system. In terms of application areas, the Infusion Pump market has been segmented into analgesia (pain management) clinical nutrition, diabetes, chemotherapy and others including the new biologic medication therapies fast developing.

The benefit of a wearable infusion device lies in its simplicity and convenience of use. The patient does not need to go into a doctor's office or specialty care clinic to get hooked up to an IV line for a course of treatment. Medipacs pumps are specifically designed to be worn by patients during the course of their normal daily life, at home, at work, at the restaurant or at the movies. After attaching the small device to the body, the patient needs minimal training to use the device, as it has already been pre-set by the Pharmacy to deliver a patient's specific therapeutic regimen for several days.

What is a Biologic? Biologics are a new class of medication therapy. Biologics are genetically engineered proteins derived from human genes and made from living organisms rather than synthesized from chemicals. Science has learned how to use these genes to target specific components of diseases and the organs involved rather than giving the patient drugs which affect the entire body. Biologics are structured to only target specific parts of the body, i.e. arthritis, immune system that cause inflammation. The rest of the body isn't impacted by the biological medication.

Wearable Infusion Pumps are needed to deliver biologic drugs under the skin as biologic medication are destroyed by stomach acids if taken orally within the GI Tract.

Research estimates (by Roots) indicate that more than 100 pharmaceutical companies are currently targeting wearable infusion devices. The report further identifies 250 drugs ranging from approved products to early stage molecules and estimated that up to 350 million wearable injectors will be used every year by 2024. The first wave of biologics launched in a wearable injector will appear in 2015-2016. It is predicted that within five years between 50 and 100 million wearable injectors will be required per year before ramping to 350 million.

Wearable injectors and more programmable wearable infusion pumps are poised to rapidly become one of the most important methods to self-administer complex biologics into the body over the next 10 years, dramatically improving patient quality of life and therapy compliance while reducing healthcare costs.

## **MEDIPACS - FIRST APPLICATION: PAIN MANAGEMENT**

The analgesia or pain management infusion pump market can be segmented as post-surgery application, labour pain, accident and trauma, and cancer patients.

## **VETERINARIAN MARKET/ANIMAL HEALTH SECTOR**

CBD and Medipacs plan to launch a veterinary infusion pump to treat canines, Q4 2015, for specific pain medications, with other use cases to follow.

CBD, "the Company" estimates the Medipacs **Mini-Infuser™ CRI Pump**, will be available for sale, in Canada, to veterinary surgical hospitals in Q4 2015, for companion animal use and the company will also begin to solicit relationships with pharmaceutical companies developing biologics (peptides, proteins, antibodies) that require a transdermal delivery system for proper dosing.

CBD, "the Company" will also solicit strategic interest and direct sales of disposable infusion pumps into veterinary surgical hospitals followed by human hospice, hospital and home care and pain medication infusion markets.

**THE MEDIPACS MINI-INFUSER™ - Platform**

High performance, scalable, thin and wearable for days

Safer and simpler for users

Wireless capability for monitoring/programming

Low Cost and Disposable

Freedom from IV access: Subcutaneous Delivery

Reduces infections and potentially shortens hospital stays

Patient mobility = any care location and better quality of life

Substantially reduces in health care costs

**SUMMARY OF TRANSACTION:**

CBD Med Research Corp. will acquire the Canadian exclusive sales and distribution rights to the **Mini-Infusion™CRI Pump** for veterinary purposes. In addition, CBD will acquire the Canadian exclusive sales and distribution right to the **Mini-Infuser PRN Pump** in development for human pain relief.

Middle East - CBD will represent Medipacs on an exclusive basis for the Middle East countries to develop product distribution.

CBD/Medipacs Partnership: Digital Health Sector Projects. The companies intend to cooperate on future projects. It's apparent that other wireless cloud based applications, such as key vital sign sensors, tablet communications and user interface software development could be configured for additional healthcare applications. The companies anticipate the new development projects to be structured on a 51% ownership basis to Medipacs and 49% to CBD ownership basis, should the parties elect to proceed.

CBD will issue to Medipacs up to 19% (min 15%) of its common shares on closing of the definitive agreement. (approximately 2,769,999 common shares to Medipacs).

CBD estimates that it will have approximately 14,574,999 shares issued post financing and approximately 17,344,998 issued on closing of the transaction with Medipacs Inc.

CBD will organize, coordinate and finance trial development testing with high standard veterinary institutions in Canada, for the Vet CRI, up to a 30 canine patient study, up to \$50,000.00 Cdn.

CBD will provide a study (up to \$50,000.00 Cdn) for development of the human pain device at high standard medical institutions in Canada.

CBD will prepare and finance the introduction marketing of the mini-infusion device in Canada.

CBD will invest a minimum of \$100,000.00 into Medipacs and CBD will also have the rights to invest a further \$400,000.00 for a total of 500K of Medipacs convertible notes or equity shares in the current preferred "C" round or D round as may be available at the time.

### **CBD Med Research Corp. Private Placement – Financing**

Private placement financing, CBD will issue up to 6,666,666 units to raise up to \$400,000.00 on closing the transaction. Each unit will be priced at 0.06 cent with a one- year warrant exercisable at 0.08 cents. A Finders Fee of 8% of private placement proceeds may be paid.

Transaction Finder Fees – CBD will issue a finders fee related to the transaction of 200,000 common shares of CBD.

### **Change of Business**

The above transaction is an official change of business and will be subject to regulatory and stock exchange approvals.

[www.cbdmedresearch.com](http://www.cbdmedresearch.com)

[www.medipacs.com](http://www.medipacs.com)

On behalf of the Board of Directors,

**CBD Med Research Corp.**

"Gary F. Zak"

President, CEO

Email: [gzak1@shaw.ca](mailto:gzak1@shaw.ca)

Tel: 604-802-7551

*Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.*

*This news release includes certain statements that may be deemed “forward-looking statements”. All statements in this release, other than statements of historical facts, including the likelihood of commercial mining and possible future financings are forward-looking statements. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in the forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include unsuccessful business , changes in forecast prices, changes in the availability of funding for proposed business plans, unanticipated changes in key management personnel and general economic conditions. Accordingly the actual events may differ materially from those projected in the forward-looking statements. For more information on the Company and the risks and challenges of its business, investors should review the Company’s annual filings that are available at [www.sedar.com](http://www.sedar.com).*